Rick Doblin, PhD, is the Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), a nonprofit organization advancing research into the therapeutic potential of psychedelics. He studied under Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. Rick aims to develop legal contexts for the beneficial uses of psychedelics and marijuana.

The path to healing trauma and advancing mental health care through psychedelic therapies is often blocked by regulatory barriers, cultural stigma, and skepticism. While MDMA-assisted psychotherapy shows immense promise, therapists wonder how these treatments can be made widely accessible and trusted, especially across different cultures, age groups, and medical systems. What does it take to shift public perception and institutional acceptance?

Psychedelic researcher and therapy pioneer Rick Doblin combines rigorous clinical research, international therapist training, and grassroots cultural change to reduce the stigma surrounding psychedelic therapies. He has initiated humanitarian projects in high-trauma, low-resource regions like Ukraine and Rwanda and facilitated the FDA approval process through pilot studies and collaborative research. Rick emphasizes the importance of therapist training — including firsthand MDMA experience — and encourages public storytelling to destigmatize psychedelics and build broader support.

In today’s episode of Living Medicine, Dr. Sandy Newes welcomes Rick Doblin, PhD, Founder and President of MAPS, to discuss his pioneering research into MDMA and other psychedelic-assisted psychotherapies. Rick talks about group and family psychedelic therapy models, the relationship between mysticism and therapeutic outcomes during psychedelic sessions, and how to support natural emotions during vulnerable states.